(ARCT) Arcturus Therapeutics - Ratings and Ratios
Vaccine, Therapeutics, mRNA, Rare Diseases, Infectious Disease
ARCT EPS (Earnings per Share)
ARCT Revenue
Description: ARCT Arcturus Therapeutics
Arcturus Therapeutics Holdings Inc is a biotechnology company focused on developing mRNA-based therapeutics and vaccines for infectious diseases and rare genetic disorders. The companys technology platforms, LUNAR lipid-mediated delivery and STARR mRNA, enable the development of innovative treatments. Key pipeline products include ARCT-810 for ornithine transcarbamylase deficiency, ARCT-032 for cystic fibrosis, and various COVID-19 and influenza vaccine candidates.
From a business perspective, Arcturus Therapeutics has a diverse pipeline with multiple products in various stages of clinical trials, indicating a potentially significant revenue stream in the future. The companys market capitalization is approximately $390.81 million, and its forward P/E ratio is 2.48, suggesting a relatively low valuation compared to its future earnings potential.
To further evaluate the companys prospects, key performance indicators (KPIs) such as cash burn rate, research and development (R&D) expenses as a percentage of revenue, and pipeline product success rates can be considered. Given the companys current stage, a high R&D expense ratio is expected. Monitoring the progress of its pipeline products, particularly those in Phase 2 and Phase 3 clinical trials, will be crucial in assessing the companys future prospects.
Some key metrics to watch include the companys quarterly earnings reports, updates on clinical trial progress, and any strategic partnerships or collaborations that may impact its financials or pipeline development. Additionally, the competitive landscape of the mRNA therapeutics and vaccines market, including the presence of major players such as Moderna and Pfizer, should be considered when evaluating Arcturus Therapeutics potential market share and growth prospects.
ARCT Stock Overview
| Market Cap in USD | 462m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-04-16 |
ARCT Stock Ratings
| Growth Rating | -31.9% |
| Fundamental | 19.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -28.9% |
| Analyst Rating | 4.73 of 5 |
ARCT Dividends
Currently no dividends paidARCT Growth Ratios
| Growth Correlation 3m | 63.5% |
| Growth Correlation 12m | -60.7% |
| Growth Correlation 5y | -64.9% |
| CAGR 5y | 3.65% |
| CAGR/Max DD 3y | 0.05 |
| CAGR/Mean DD 3y | 0.11 |
| Sharpe Ratio 12m | -0.91 |
| Alpha | -27.35 |
| Beta | 0.632 |
| Volatility | 70.94% |
| Current Volume | 644.2k |
| Average Volume 20d | 511.5k |
| Stop Loss | 16.1 (-7%) |
| Signal | -0.66 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-60.2m TTM) > 0 and > 6% of Revenue (6% = 7.05m TTM) |
| FCFTA -0.20 (>2.0%) and ΔFCFTA -14.12pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 194.0% (prev 173.6%; Δ 20.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.21 (>3.0%) and CFO -64.9m <= Net Income -60.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.90 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (27.1m) change vs 12m ago 0.60% (target <= -2.0% for YES) |
| Gross Margin 98.54% (prev 97.67%; Δ 0.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 33.67% (prev 37.83%; Δ -4.16pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -7.37
| (A) 0.74 = (Total Current Assets 274.5m - Total Current Liabilities 46.5m) / Total Assets 309.3m |
| (B) -1.53 = Retained Earnings (Balance) -472.1m / Total Assets 309.3m |
| warn (B) unusual magnitude: -1.53 — check mapping/units |
| (C) -0.13 = EBIT TTM -46.2m / Avg Total Assets 348.9m |
| (D) -6.03 = Book Value of Equity -472.0m / Total Liabilities 78.2m |
| Total Rating: -7.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 19.38
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -17.57% = -5.0 |
| 3. FCF Margin -51.40% = -7.50 |
| 4. Debt/Equity 0.34 = 2.44 |
| 5. Debt/Ebitda -1.79 = -2.50 |
| 6. ROIC - WACC -25.95% = -12.50 |
| 7. RoE -24.87% = -2.50 |
| 8. Rev. Trend -15.02% = -0.75 |
| 9. Rev. CAGR 31.35% = 2.50 |
| 10. EPS Trend -32.59% = -0.81 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ARCT shares?
Over the past week, the price has changed by -2.91%, over one month by -9.93%, over three months by +34.58% and over the past year by -15.96%.
Is Arcturus Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARCT is around 16.73 USD . This means that ARCT is currently overvalued and has a potential downside of -3.41%.
Is ARCT a buy, sell or hold?
- Strong Buy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 69.9 | 303.5% |
| Analysts Target Price | 69.9 | 303.5% |
| ValueRay Target Price | 18.4 | 6.4% |
Last update: 2025-09-01 04:34
ARCT Fundamental Data Overview
CCE Cash And Equivalents = 196.5m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 2.4777
P/S = 3.7823
P/B = 1.9991
Beta = 2.265
Revenue TTM = 117.5m USD
EBIT TTM = -46.2m USD
EBITDA TTM = -43.7m USD
Long Term Debt = 31.7m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 46.5m USD (from totalCurrentLiabilities, last quarter)
Debt = 78.2m USD (Calculated: Short Term 46.5m + Long Term 31.7m)
Net Debt = -173.5m USD (from netDebt column, last quarter)
Enterprise Value = 343.6m USD (461.9m + Debt 78.2m - CCE 196.5m)
Interest Coverage Ratio = unknown (Ebit TTM -46.2m / Interest Expense TTM 0.0)
FCF Yield = -17.57% (FCF TTM -60.4m / Enterprise Value 343.6m)
FCF Margin = -51.40% (FCF TTM -60.4m / Revenue TTM 117.5m)
Net Margin = -51.20% (Net Income TTM -60.2m / Revenue TTM 117.5m)
Gross Margin = 98.54% ((Revenue TTM 117.5m - Cost of Revenue TTM 1.72m) / Revenue TTM)
Tobins Q-Ratio = -0.73 (set to none) (Enterprise Value 343.6m / Book Value Of Equity -472.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 78.2m)
Taxrate = 21.0% (US default)
NOPAT = -46.2m (EBIT -46.2m, no tax applied on loss)
Current Ratio = 5.90 (Total Current Assets 274.5m / Total Current Liabilities 46.5m)
Debt / Equity = 0.34 (Debt 78.2m / last Quarter total Stockholder Equity 231.1m)
Debt / EBITDA = -1.79 (Net Debt -173.5m / EBITDA -43.7m)
Debt / FCF = -1.30 (Debt 78.2m / FCF TTM -60.4m)
Total Stockholder Equity = 241.9m (last 4 quarters mean)
RoA = -19.45% (Net Income -60.2m, Total Assets 309.3m )
RoE = -24.87% (Net Income TTM -60.2m / Total Stockholder Equity 241.9m)
RoCE = -16.90% (Ebit -46.2m / (Equity 241.9m + L.T.Debt 31.7m))
RoIC = -18.82% (NOPAT -46.2m / Invested Capital 245.7m)
WACC = 7.13% (E(461.9m)/V(540.1m) * Re(8.34%)) + (D(78.2m)/V(540.1m) * Rd(0.0%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 48.48 | Cagr: 0.22%
Discount Rate = 8.34% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -60.4m)
Revenue Correlation: -15.02 | Revenue CAGR: 31.35%
Rev Growth-of-Growth: -16.18
EPS Correlation: -32.59 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 74.20
Additional Sources for ARCT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle